Last reviewed · How we verify
Ilomedin
Ilomedin is a Small molecule drug developed by Prim PD Dr Afshin Assadian. It is currently in Phase 2 development for Pulmonary arterial hypertension. Also known as: Product Code 1-22460, ATC Code: B01AC11, concentrate and solvent for injection, Iloprost.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ilomedin |
|---|---|
| Also known as | Product Code 1-22460, ATC Code: B01AC11, concentrate and solvent for injection, Iloprost |
| Sponsor | Prim PD Dr Afshin Assadian |
| Target | Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Approved indications
- Pulmonary arterial hypertension
Common side effects
Key clinical trials
- Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude
- Infusion of Prostacyclin vs Placebo for 72-hours in Mechanically Ventilated Patients With Acute Respiratory Failure (PHASE2)
- Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure (PHASE2)
- A Clinical Trial Investigating Iloprost as Medication to Improve Bone Healing in Patients With Proximal Humeral Fracture (PHASE1, PHASE2)
- Endothelial Dysfunction in Resuscitated Cardiac Arrest (PHASE2)
- Iloprost for Bridging to Heart Transplantation in PH (PHASE2)
- The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation (PHASE2)
- Co-administration of Iloprost and Eptifibatide in Septic Shock Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ilomedin CI brief — competitive landscape report
- Ilomedin updates RSS · CI watch RSS
- Prim PD Dr Afshin Assadian portfolio CI
Frequently asked questions about Ilomedin
What is Ilomedin?
What is Ilomedin used for?
Who makes Ilomedin?
Is Ilomedin also known as anything else?
What development phase is Ilomedin in?
What does Ilomedin target?
Related
- Target: All drugs targeting Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype
- Manufacturer: Prim PD Dr Afshin Assadian — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Pulmonary arterial hypertension
- Also known as: Product Code 1-22460, ATC Code: B01AC11, concentrate and solvent for injection, Iloprost